I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB) has been added to the MSCI China All Shares Index, effective May 27, 2021. This inclusion follows the company's recent addition to the NASDAQ Biotechnology Index in December 2020, indicating its growing recognition among global investors. The MSCI China Index includes large and mid-cap Chinese stocks, offering a benchmark for equity exposure. I-Mab aims to progress as a fully integrated global biopharmaceutical entity and is advancing key pipeline products, including felzartamab, lemzoparlimab, and uliledlimab.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced its participation in several conferences during May 2021. Key events include the HSBC 8th Annual China Conference from May 11-21, the CICC 2021 Healthcare Investment Forum on May 18, the Macquarie D.E.L.T.A.H. China Conference on May 21, and the Morgan Stanley China Summit from May 26-28. Management representatives will include Chairman Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. These conferences aim to provide insights into the company’s novel biologics and clinical pipeline developments.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced it filed its annual report on Form 20-F for the year ended December 31, 2020, with the SEC on April 28, 2021. This report is accessible via the company's investor relations website and the SEC's site. I-Mab focuses on developing novel biologics in the immuno-oncology field and aims to transition from a clinical-stage to a fully integrated global biopharmaceutical company. The company has over 15 drug candidates in its pipeline and operates globally, including in China and the U.S.

I-Mab (Nasdaq: IMAB) has announced positive topline results from its Phase 2 clinical study of olamkicept for treating active ulcerative colitis (UC). This randomized, double-blind trial showed that patients receiving 600 mg olamkicept biweekly had significantly higher clinical response rates after 12 weeks compared to placebo (p=0.032). Key secondary endpoints, including clinical remission and mucosal healing, were also met (p<0.001). The drug demonstrated a favorable safety profile. I-Mab aims to expand olamkicept's market reach, exploring collaborations in the U.S., Canada, and Europe.

I-Mab (Nasdaq: IMAB) has announced that its abstract on the CD73 antibody, uliledlimab, has been selected for a poster presentation at the 2021 ASCO Annual Meeting scheduled for June 4-8, 2021. This antibody is designed to modulate the tumor microenvironment and enhance anti-tumor responses, particularly when combined with PD-(L)1 inhibitors. Preliminary clinical studies have shown that uliledlimab is safe and well tolerated, demonstrating clinical activity in patients with advanced solid tumors. Further research is ongoing to validate its efficacy.

I-Mab (Nasdaq: IMAB) and ABL Bio (Kosdaq: 298380) announce the dosing of the first patient in a Phase 1 trial for bispecific antibody TJ-L14B/ABL503. This trial aims to assess the safety and efficacy of the antibody in treating locally advanced or metastatic solid tumors (NCT04762641). Developed using ABL's 'Grabody-T' technology, the bispecific antibody targets PD-L1 and engages T-cell activation to enhance antitumor activity while reducing off-tumor toxicity. Initial results suggest improved efficacy over traditional treatments.

I-Mab (Nasdaq: IMAB) announced its participation in several key conferences in April 2021, showcasing its commitment to advancing immuno-oncology therapeutics. Notable events include the 20th Annual Needham Healthcare Conference and the 2021 Haitong Securities Spring Listed Companies Conference, where management presentations by key executives such as Dr. Jingwu Zang and Ms. Leah Liu will take place. The company continues to evolve from a clinical-stage biotech entity to a fully integrated global biopharmaceutical company, with a robust pipeline of over 15 drug candidates.

I-Mab (Nasdaq: IMAB) and ABL Bio, Inc. have received FDA approval for their Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for the bispecific antibody TJ-CD4B/ABL111. This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors. The antibody targets Claudin 18.2, enhancing immune response specifically at tumor sites while minimizing side effects. Both companies are optimistic about advancing this promising therapeutic option.

I-Mab (Nasdaq: IMAB) announced robust full-year results for 2020, achieving net revenues of RMB 1,542.7 million (US $236.4 million) and corporate profitability. Notably, the company has made significant strides in its clinical pipeline, achieving 18 milestones since its IPO, with three registrational trials currently underway. The New Drug Application for felzartamab (TJ202) is on track for submission in 2021. A global collaboration with AbbVie aims to advance the CD47 antibody lemzoparlimab (TJC4). The company holds a total cash position of RMB 4.8 billion (US $734.1 million), supporting operations through 2023.